|
2014/09/02
Abe H1), Sasada A1), Tabata A1), Kawasaki H2)
1) Abe Cacner Clinic
2) The Life Science Institute Co. Ltd
Abstract
[Back ground]
This study was conducted to evaluate the efficacy and safety of multi peptides DC-based vaccine in patients with non-small
cell lung cancer (NSCLS).
[Methods]
DC vaccine was manufactured by novel technique without “apheresis”. Multi peptides used in this study were WT1, MUC1,
CEA, CA125, Survivn, Her2, NY-ESO-1 according to result of HLA typing. 34 (thirty four) advanced NSCLC patients who failed
to standard therapy were enrolled in this study.
DC-based vaccine was injected intradermally to the axillary or inguinal regions in 2 separate area at 6 times in 2 week interva
l. ELISPOT assay was performed before and at the end of one Kur of the study.
[Results]
The DC-based vaccine was well tolerated without any adverse events of grade 2 or higher.
After 6 DC vaccine injected, among 34 patients with NSCLC, response rate was 26.5% and cancer control ratio was 55.9%.
The patients were divided into 2 groups, one was used 2 or less peptides (group A),
the other was used more than 3 peptides (group B).
In group A, response rate and control ratio were 22.2% and 55.5% respectively.
On the other hand, in group B, response rate and control ratio were 28.0% and 56.0% respectively.
This data suggests that multi peptides pulsed DC vaccine shows better clinical outcome in terms of response rate in
patients with NSCLC.
[Conclusions]
DC-based vaccine pulsed with multi peptides was safety and useful for the treatment of advanced NSCLC refractory to
standard therapy and therefore warrants further clinical studies.
• 2014 면역치료, 백신학회
August 11 - 14, 2014, Boston, USA
|
